News - Ambergen Inc.

April 2022

AmberGen announces that Dr. Michael Easterling, PhD will join Board of Directors

April 2022

AmberGen Announces New Appointments for John Gillespie & Dr. Kenneth J. Rothschild

April 2022

AmberGen and Bruker Collaborate on Spatial Biology Imaging Reagents for MALDI-Immunohistochemistry (MALDI-IHC)

March 2022

Dr. Mark Lim of AmberGen was honored to be an invited keynote speaker at the “Innovation in Mass Spectrometry Imaging Omics” Session

February 2022

The paper “Highly Multiplexed Immunohistochemical MALDI-MS Imaging of Biomarkers in Tissues” was published in The Journal of the American Society for Mass Spectrometry

February 2022

Dr. Mark Lim of AmberGen gave an invited presentation sponsored by Bruker at the European Association for Cancer Research (EACR)

October 2021

Dr. Mark Lim Presentation at Bruker’s “Virtual eXceed Symposia and Breakfast Workshops: Expanding the Horizons of Singe Cell Research” during ASMS 2021 in Philadelphia.

July 2020

AmberGen awarded a $2.5 million, 2-year Phase II SBIR grant from NIH-NIA

November 2019

Dr. Gargey Yagnik, PhD is appointed as Director of Mass Spectrometry

October 2018

AmberGen receives US Patent 10,088,474 for its pioneering PC-PURE technology for multiplex Allergy diagnostics

August 2018

AmberGen receives US Patent 10,060,912 for global proteomic screening of random bead-arrays using mass spectrometric imaging

March 2018

AmberGen receives US Patent 9,910,034 for its innovative PC-PURE technology for photo-affinity biomarker enrichment

March 2018

AmberGen receives US Patent 9,910,034 increasing its broad coverage on PC-PURE™ photo-affinity biomarker purification and enrichment technology for improving the accuracy of diagnostic testing

February 2018

Paper published in PLOS ONE in collaboration with Boston Children’s Hospital “Photocleavage-based affinity purification of biomarkers from serum: Application to multiplex allergy testing” describing application of AmberGen’s PC-PURE™ to highly multiplex in vitro allergy testing (AllerBead™)

January 2018

AmberGen awarded $2 million, 2-year Phase IIb SBIR grant from NIH-NIAID to further develop its PC-PURE™-assisted, multiplex, in vitro AllerBead™ assay which uses finger-stick blood for the highly multiplex quantification of allergen-specific IgE

February 2017

AmberGen acquires a new state-of-the-art Bruker rapifleX™ MALDI mass spectrometer for ultra-fast and high resolution mass spectrometry imaging of its Bead-AMS™ proteomic bead-arrays

January 2017

Dr. Gargey Yagnik joins AmberGen as Program Coordinator for Mass Spectrometry. In his previous position as a postdoctoral researcher at Sanofi Genzyme he developed new methods for MALDI-MSI tissue imaging. He received his Ph.D. from Iowa State University in analytical chemistry.

December 2016

AmberGen awarded two US Patents (9,513,285 and 9,523,680) providing broad coverage for its Bead-AMS™ technologies

December 2016

AmberGen Founder and Chairman of the Board, Dr. Ken Rothschild, was elected as a Fellow of the National Academy of Inventors (NAI). The election as an NAI Fellow honors contributions from inventors who have made a tangible impact on quality of life, economic development and welfare of society.

November 2016

AmberGen pioneers new Bead Array Mass Spectrometry Technology (Bead-AMS™) and is awarded 3 U.S. patents providing broad coverage

September 2016

AmberGen awarded 3-year Phase II SBIR grant from NIH-NIGMS to develop Bead-AMS™ for screening on- and off-target drug binding on a proteome-wide scale

July 2016

AmberGen awarded Phase I SBIR grant from NIH-NCI IMAT program to develop PC-PURE™ for the detection of serological ovarian cancer biomarkers

May 2016

Paper published in Nature’s Scientific Reports “Proteome-wide drug screening using mass spectrometric imaging of bead-arrays” describing drug-discovery application of Bead-AMS™ including detection of on- and off-target drug binding

May 2016

AmberGen receives US Patent 9,334,530 for its Bead-AMS™ technology describing synchronization of mass spectrometric and fluorescence images of mass-tagged bead arrays

July 2015

John Gillespie, former Director of R&D for 3 Johnson & Johnson businesses including their multi-billion dollar Ethicon Products business, joins AmberGen as VP of Product and Business Development

February 2015

Paper published in Liver International “Anti-Kelch-like 12 and Anti-Hexokinase 1: Novel Autoantibodies in Primary Biliary Cirrhosis” resulting from a collaboration between AmberGen, INOVA Diagnostics and MGH

January 2015

AmberGen receives US Patent 8,932,879 for its pioneering PC-PRINT™ technology

December 2014

AmberGen receives US Patent 8,906,700 providing broad coverage on PC-PURE™ technology for biomarker isolation and use in highly sensitive and quantitative assays

October 2014

AmberGen and Massachusetts General Hospital (MGH) are awarded US Patent 8,852,956 for two new diagnostic autoantigen biomarkers for the autoimmune liver disease Primary Biliary Cirrhosis (PBC)

July 2014

AmberGen awarded 2-year Phase II SBIR grant for use of photocleavable peptide and peptoid bead-libraries in screening biomolecular interactions

February 2014

AmberGen awarded 3-year Phase II SBIR grant from NIH-NIAID for development of a multiplex in vitro pediatric allergy test

January 2014

Paper published in Rapid Communications in Mass Spectrometry “Correlated matrix-assisted laser desorption/ionization mass spectrometry and fluorescent imaging of photocleavable peptide-coded random bead-arrays” describing proteomic applications of Bead-AMS™

December 2013

Paper published in Journal of Immunological Methods “Multiplexed VeraCode bead-based serological immunoassay for colorectal cancer” detailing the development of a serological assay for colorectal cancer biomarkers based on the novel use of the VeraCode™ multiplex bead assay system

August 2013

AmberGen receives US Patent 8,507,648 for novel method of detecting protease activity using mass spectrometry

July 2013

AmberGen receives US Patent 8,486,634 for novel method of detecting DNA methylation using solid-phase PCR

July 2013

AmberGen receives US Patent 8,481,263 for creating self-assembled bead-protein libraries by solid-phase PCR and nascent protein expression

October 2012

AmberGen receives US Patent 8,288,098 for a novel method of DNA sequencing using nucleotides having cleavable detectable labels

October 2012

AmberGen receives US Patent 8,278,045 for detecting chain truncation mutations which cause breast and colorectal cancer

September 2012

AmberGen awarded Phase I SBIR grant for the application of photocleavable bead technology to glycomics

April 2012

AmberGen receives US Patent 8,148,062 for detecting disease causing genetic mutations such as breast and colorectal cancer using affinity tags in translated nascent proteins